| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF00568400 |
| P698 | PubMed publication ID | 7202473 |
| P2093 | author name string | A Somogyi | |
| M Eichelbaum | |||
| G E von Unruh | |||
| H J Dengler | |||
| P2860 | cites work | Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data | Q30558717 |
| The metabolism of DL-[14C]verapamil in man | Q39263239 | ||
| Verapamil: a review of its pharmacological properties and therapeutic use. | Q39720756 | ||
| GLC Assay of Verapamil in Plasma: Identification of Fluorescent Metabolites after Oral Drug Administration | Q41507555 | ||
| Pharmacokinetics of verapamil in man | Q41520033 | ||
| Influence of meso-caval shunt surgery on verapamil kinetics, bioavailability and response | Q43242625 | ||
| Fluorometric Assay of Verapamil in Biological Fluids and Tissues | Q44892136 | ||
| Physiology and pharmacology of sodium, potassium, and calcium movements across the membrane | Q46878092 | ||
| Number of exponential terms describing the solution of an N-compartmental mammillary model: vanishing exponentials | Q52771334 | ||
| Determination of verapamil in human plasma by mass fragmentography using stable isotope-labelled verapamil as internal standard | Q52821925 | ||
| [A new group of competitive divalent Ca-antagonists (iproveratril, D 600, prenylamine) with potent inhibitory effects on electromechanical coupling in mammalian myocardium] | Q54073509 | ||
| Statistical estimations in pharmacokinetics. | Q54597722 | ||
| Physiological disposition of verapamil in man | Q57072038 | ||
| Differences between the Plasma Indocyanine Green Disappearance Rates of Normal Men and Women | Q58817424 | ||
| Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets | Q70681056 | ||
| P4510 | describes a project that uses | stable isotope | Q878130 |
| P433 | issue | 2 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| stable isotope | Q878130 | ||
| P304 | page(s) | 133-137 | |
| P577 | publication date | 1981-01-01 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. | |
| P478 | volume | 19 |
| Q45798731 | A review of the human metabolism and pharmacokinetics of nicardipine hydrochloride |
| Q40267429 | Application of stable labelled drugs in clinical pharmacokinetic investigations |
| Q28740996 | Applications of stable isotopes in clinical pharmacology |
| Q40146301 | Calcium Antagonists Pharmacokinetic Properties |
| Q36053380 | Chronopharmacology of intravenous and oral modified release verapamil. |
| Q40167931 | Clinical Pharmacokinetics of Verapamil |
| Q70478662 | Clinical pharmacokinetics of verapamil in patients with atrial fibrillation |
| Q39754378 | Clinical pharmacokinetics of verapamil, nifedipine and diltiazem |
| Q46538718 | Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension |
| Q39679813 | Controlled-release formulations of propranolol and verapamil |
| Q70144338 | Evaluation of the utility of a proposed method for correcting for intrasubject variability in metabolic clearance in the bioavailability assessment of theophylline |
| Q34257205 | First-pass elimination. Basic concepts and clinical consequences |
| Q44632963 | HPLC/MS findings in a fatality involving sustained-release verapamil |
| Q40791116 | Individual variation in first-pass metabolism |
| Q71324315 | Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil |
| Q40263538 | New antiarrhythmic drugs: their place in therapy |
| Q40184283 | Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies |
| Q69426469 | Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man |
| Q42532060 | Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration |
| Q60777249 | Pharmacokinetics of sustained-release verapamil after a single administration and at steady state |
| Q69720626 | Pharmacokinetics of verapamil in patients with hypertension |
| Q49323041 | Pharmacokinetics of verapamil in patients with renal failure |
| Q34448937 | Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis |
| Q42246990 | Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations |
| Q67868794 | Plasma level monitoring of d,l-verapamil and three of its metabolites by reversed-phase high-performance liquid chromatography |
| Q36647102 | Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data |
| Q43554159 | Race but not age affects erythromycin breath test results in older hypertensive men. |
| Q36003980 | Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart |
| Q54117272 | Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope. |
| Q80084101 | Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers |
| Q42126042 | Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique |
| Q70681056 | Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets |
| Q52564191 | The assessment of bioavailability in the presence of nonlinear elimination. |
| Q39459895 | The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review |
| Q80266410 | Validation of the hepatic blood flow rate model for verapamil first-pass metabolism |
| Q69785638 | Verapamil and norverapamil in plasma and breast milk during breast feeding |
| Q34622354 | Verapamil disposition--effects of sulphinpyrazone and cimetidine |
| Q40253273 | Verapamil hydrochloride: pharmacological properties and role in cardiovascular therapeutics |
| Q49311589 | Verapamil-rifampin interaction |
| Q38679740 | Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension |
Search more.